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Abstract
Purpose Dodecafluoropentane emulsion (DDFPe) is a per-
fluorocarbon with high oxygen dissolving, transport, and de-
livery capacity that may offer the potential to limit ischemic
injury prior to clinical reperfusion. Here we investigated the
cardiac protective potential of DDFPe in a mouse model of
myocardial infarction.
Methods Myocardial infarction was initiated by permanent
ligation of the left anterior descending (LAD) coronary artery.
Mice were administered vehicle or 5-hydroxydecanoate (5-
HD) intravenously 10 min before LAD occlusion followed by
a single intravenous administration of vehicle or DDFPe
immediately after occlusion. Heart tissue and serum samples
were collected 24 after LAD occlusion for measurement of
infarct size and cardiac troponin I (cTnI) levels, respectively.
Results DDFPe treatment reduced infarct size by approxi-
mately 72 % (36.9±4.2 % for vehicle vs 10.4±2.3 % for
DDFPe; p<0.01; n=6–8) at 24 h. Serum cTnI levels were
similarly reduced by DDFPe (35.0±4.6 ng/ml for vehicle vs
15.8±1.6 ng/ml for DDFPe; p<0.01; n=6–8). Pretreatment
with 5-HD, a mitochondrial ATP-sensitive potassium channel
(mitoKATP) inhibitor, blocked the reduction in infarct size
(29.2±4.4 % for 5-HD vs 35.4±7.4 % for 5-HD+DDFPe;
p=0.48; n=6–8) and serum cTnI levels (27.4±5.1 ng/ml for
5-HD vs 34.6±5.3 ng/ml for 5-HD+DDFPe; p=0.86; n=6–8)
by DDFPe.
Conclusion Our data indicate a cardiac protective role of
DDFPe that persists beyond its retention time in the body
and is dependent on mitoKATP, an important mediator of
ischemic preconditioning induced cardiac protection.
Keywords Myocardial infarction . Perfluorocarbons .
Dodecafluoropentane
Introduction
Myocardial infarction as a result of coronary heart disease is a
serious health concern, accounting for more deaths each year
than any other individual disease [1]. Myocardial infarction
occurs due to occlusion of one or more arteries, typically a
coronary or branching artery, supplying the myocardium.
Arterial occlusion results in ischemia of the downstream tis-
sue, which cause myocardial damage and necrosis. Since the
heart is a terminally differentiated tissue with limited regener-
ative potential, any loss of cardiac myocytes and contractile
machinery can adversely impact cardiac function. It is there-
fore imperative that myocardial damage is limited, and the
most effective therapy is the reperfusion of the ischemic
tissue. Myocardial damage begins within 20 to 30 min of the
ischemic period, with irreversible myocyte necrosis occurring
over the course of several hours. The best clinical outcomes
are observed when reperfusion is initiated within 2 h after the
onset of symptoms [2, 3]. Percutaneous coronary intervention
(PCI) is a mainstay for reperfusion therapy. One issue with
PCI is the time between first medical contact and the start of
the procedure, or door-to-balloon time. Reports indicate that
the average door-to-balloon time for patients arriving at a
facility capable of PCI is 60 min. In cases where inter-
hospital transfer is required for PCI only 33 % have a door-
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to-balloon time of less than 90min and only 66% have a door-
to-balloon time of less than 120 min [4]. Furthermore, the
mean symptom duration time of MI before first medical
contact is 2 h. As a result most patients receive intervention
well outside of the optimal 2 h window, highlighting the need
for therapeutic options that extend the timeframe for optimal
reperfusion.
Perfluorocarbon (PFC) based oxygen carriers represent an
intriguing option for treating ischemic conditions. PFCs are
highly inert compounds with the ability to dissolve, transport,
and deliver significant amounts of oxygen and other gases [5,
6]. PFC emulsions offer particular promise for oxygen deliv-
ery. Important for application to the treatment of ischemic
tissue is the small particle size (~200 nm) of PFC emulsions
that can be produced. The small size of these PFC emulsions
may allow passage through many vascular occlusions that
prevent the movement of larger red blood cells. A comparison
of three PFC emulsions identified dodecafluoropentane emul-
sion (DDFPe) as having greater oxygen delivery capacity [7].
Among other PFCs, this increased oxygen capacity is unique
to DDFPe, which undergoes gaseous expansion that increases
intramolecule pockets for dissolving respiratory gasses at
physiological temperatures.
The utility of DDFPe as an oxygen delivery system has
been demonstrated in vivo. In addition, the therapeutic poten-
tial of DDFPe has been applied to supplement oxygen deliv-
ery and maintain tissue viability in severely anemic rats and to
reduce infarct size in a rabbit model of ischemic stroke [8–10].
DDFPe represents a potential avenue to extend the timeframe
of reperfusion therapy and reduce infarct size following a
myocardial infarction through enhanced oxygen delivery prior
to revascularization. Here we used a mouse model of myocar-
dial infarction caused by permanent occlusion of the left
anterior descending (LAD) coronary artery to investigate the




2,2,2-tribromoethanol (avertin) was diluted with 2-methyl-2-
butanol and phosphate buffered saline (PBS) and was given
intraperitoneally at a dose of 400 mg/kg. Avertin, 5-
hydroxydecanoate (5-HD), and 2-methyl-2-butanol were pur-
chased from Sigma-Aldrich (St. Louis, MO). 5-HD was dilut-
ed with PBS for a final concentration of 5 mg/ml. 5-HD was
injected 5 min prior to LAD ligation at a dose of 10 mg/kg.
2 % (weight/volume) Dodecafluoropentane emulsion
(DDFPe) was given at a dose of 0.6 ml/kg. DDFPe was
diluted with PBS to a total volume of 200 μl prior to injection
into the left jugular vein. DDFPe was a generous gift from
NuvOx Pharma (Tucson, AZ). Buprenorphine slow release
was used for intraoperative and postoperative pain control at
the dose of 1 mg/kg given subcutaneously given immediately
before the operation. Buprenorphine slow release was pur-
chased through the University of Arizona’s animal care
department.
Surgical Procedure
Animal experiments were performed according to the protocol
approved by the University of Arizona Institutional Animal
Care and Use Committee. Studies conformed to the ‘Guide for
the Care and Use of Laboratory Animals’ published by the US
National Institutes of Health (NIH Publication No. 85-23,
revised 1996). Male C57BL/6 J mice, age 8–12 weeks, were
randomized into four groups: vehicle, DDFPe, 5-HD+vehi-
cle, and 5-HD+DDFPe. Mice were administered saline (ve-
hicle and DDFPe groups) or 5-HD (5-HD+vehicle and 5-
HD+DDFPe groups) intravenously (IV) via the left jugular
vein 5 min prior to occlusion of the left anterior descending
coronary artery (LAD). The heart was visualized by a left
thoracotomy and 8-0 suture was used to ligate the left anterior
descending coronary artery. Immediately after LAD ligation,
vehicle (vehicle and 5-HD+vehicle groups) or DDFPe
(DDFPe and 5-HD+DDFPe groups) was administered IV
via the left jugular vein. The chest cavity was closed and the
animal was allowed to recover for 24 h. Mice were sacrificed
24 h after LAD ligation for collection of blood and infarct
quantification.
Infarct Quantification
Trypan blue dye (2 %) was perfused through the heart via the
descending aorta to stain the non-ischemic area. The hearts
were then excised and cut in 1 mm cross sections followed by
staining in 1.5 % triphenyl tetrazolium chloride (TTC) for
30 min at 37 °C. Following TTC staining the slices were fixed
in 10% formalin and photographed. Left ventricle area, area at
risk, and infarct size were quantified using ImageJ (NIH)
planimetry. Area at risk was determined from the area not
stained by trypan blue. Infarct was represented by the area at
risk not stained red by TTC. Heart collection and infarct
quantification was performed by an individual blinded from
the surgical procedure and drug administrations.
Western Blot Analysis
Blood plasma protein concentrations were measured using the
Bradford method (Bio-Rad). Equal protein amount of each
sample were diluted in laemmli sample buffer (25 % v/v
glycerol, 2 % w/v SDS, 0.01 % w/v bromophenol blue,
350 mM dithiothreitol, 62.5 mM Tris–HCl, pH 6.8) before
10 min incubation at 95 °C. Proteins were separated by SDS-
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polyacrylamide gel electrophoresis and were transferred to
PDVF membrane. Western Blot was performed using cTnI
antibody (Abcam). Secondary antibody conjugated with
horseradish peroxidase (Santa Cruz Biotechnology) was used
for Enhanced Chemiluminescence reaction. Ponceau stain
(0.1 % w/v Ponceau S, 5 % acetic acid) was used to visualize
non-specific protein bands as loading control. cTnI band
intensity was quantified using ImageJ software (NIH) and
normalized to corresponding Ponceau loading control band
intensity.
Statistical Analysis
Student’s t-test was used to compare two means with normal
distributions as determined by the Shapiro-Wilk test. For non-
normal distributions the Mann–Whitney test was used to
compare means. A p-value of <0.05 was used as the cutoff
for statistical significance.
Results
DDFPe Reduces Infarct Size
The effect of DDFPe on infarct size was quantified from TTC
stained transverse cross sections of hearts from mice under-
going LAD occlusion (representative section image Fig. 1a).
While vehicle and DDFPe treatment groups experienced sim-
ilar sized areas at risk (46.3±2.3 % for vehicle vs 47.9±4.0 %
for DDFPe; p=0.67) (Fig. 1b), mice treated with DDFPe
immediately following LAD ligation demonstrated a reduc-
tion of infarct size, decreasing from 36.9 % of the area at risk
in vehicle treated mice to 10.4 % in mice receiving DDFPe
(p<0.01) (Fig. 1c). Release of troponin I (cTnI), a cardiac
specific isoform, into the blood is a widely used marker of MI.
Blood plasma ELISA assay for cTnI confirmed a reduction in
the extent of cardiac injury in the DDFPe treated mice as
plasma levels of cTnI were reduced from 35 ng/ml in vehicle
treated mice to 16 ng/ml in the DDFPe group (p<0.01)
(Fig. 1d).
Mitochondrial KATPAntagonist Prevents Infarct Reduction
by DDFPe
Ischemic preconditioning is a well-established, classical meth-
od of eliciting cardiac protection from ischemic insults. Inves-
tigations into the mechanisms of cardiac protection have iden-
tified mitochondrial ATP-sensitive potassium channels (KATP)
as important mediators of both ischemic and pharmacological
preconditioning in the myocardium. In order to investigate a
potential role of DDFPe in eliciting cardiac protection through
a preconditioning mechanism involving KATP, mice were ad-
ministered the selective mitochondrial KATP antagonist 5-
hydroxydecanoate (5-HD) prior to LAD ligation. Mice ad-
ministered 5-HD with or without DDFPe experienced similar
areas at risk (51 %±2.6 for 5-HD+Vehicle vs 46%±5.4 for 5-
HD+DDFPe; p=0.64) consistent with those for groups re-
ceiving vehicle or DDFPe alone (Fig. 2b). In mice treated with
5-HD, DDFPe failed to reduce infarct size measured by TTC
staining (29.2 %±4.1 for 5-HD+Vehicle vs 35.4 %±7.4 for 5-
HD+DDFPe; p=0.48) (Fig. 2c). Likewise, 5-HD attenuated
Fig. 1 DDFPe protects the heart
from myocardial infarction. Mice
were administered saline vehicle
or DDFPe immediately following
permanent LAD occlusion.
Hearts were perfused with trypan
blue 24 h after LAD ligation and
harvested for transverse
sectioning and TTC staining (a)
for assessment of the area at risk
(b) and infarct size (c). Prior to
trypan blue perfusion, heparin
treated blood was collected for
plasma preparation and cTnI
ELISA analysis (d). n=6–8.
Means±SEM are indicated next
to each group in grey. * indicates
significant difference (p<0.05)
between means, while N.S.
indicates the means are not
significantly different as
determined by Student’s t-test
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DDFPe associated decreases in cTnI release into the blood as
measured by ELISA assay (27.4±5.1 ng/ml for 5-HD vs 34.6
±5.3 ng/ml for 5-HD+DDFPe; p=0.86) (Fig. 2d). Western
blot analysis of cTnI levels in the plasma confirmed that while
DDFPe alone reduced the release of cTnI into the blood
following MI, this effect was blocked by pretreatment with
5-HD (Fig. 3a–b).
Discussion
In patients experiencing an MI, the primary concern is
reperfusion of the ischemic tissue through restoration of
blood flow through the occluded artery. Patency of the
occluded artery is often achieved clinically through the
use of percutaneous coronary intervention or the use of
thrombolytic agents. The time frame of reperfusion ini-
tiation is critical, and any delay can cause an increase in
mortality rates [11, 12]. It is therefore imperative that
re-oxygenation of the ischemic tissue occur as early as
possible. PFCs have been proposed as intravenous oxy-
gen delivery systems due to several favorable properties
including oxygen dissolving and diffusion capacities,
small size, inert nature, and non-extravasation [5, 6].
DDFPe was originally developed as an ultrasound con-
trast agent and single administration is safe in humans
[13, 14]. Furthermore, DDFPe has been demonstrated to
show therapeutic potential through oxygen delivery in
animal models of severe anemia, hemorrhagic shock,
and ischemic stroke [9, 10, 8]. The data generated here
provide clear evidence for a cardiac protective role of
DDFPe in the ischemic heart.
Consistent with previous studies investigating the protec-
tive effects of DDFPe in reducing infarct size in a rabbit model
of stroke by permanent occlusion of the middle cerebral artery
Fig. 2 5-HD attenuates DDFPe
induced cardiac protection. Mice
were pretreated with 5-HD prior
to LAD ligation and saline vehicle
or DDFPe administration. Hearts
were perfused with trypan blue
24 h after LAD ligation and
harvested for transverse section-
ing and TTC staining (a)
for assessment of the area at risk
(b) and infarct size (c). Prior to
trypan blue perfusion, heparin
treated blood was collected for
plasma preparation and cTnI
ELISA analysis (d). n=6–8.
Means±SEM are indicated next
to each group in grey. N.S.
indicates that means were
compared using Student’s t-test
Mann–Whitney rank sum were
not significantly different
Fig. 3 5-HD prevents the decrease in plasma cTnI levels by DDFPe.
Mice were pretreated with saline vehicle or 5-HD prior to LAD ligation
and saline vehicle or DDFPe administration. Blood plasma was collected
24 h after LAD ligation. Plasma samples from 6 mice in each group,
indicated by animal number, were analyzed by Western blot for cTnI
levels or ponceau stain for protein loading (a). Normalized cTnI band
intensities were graphed (b). n=6. Data is plotted as means±SEM. *
indicates significant difference (p<0.05) between means as determined
by Whitney-Man rank sum tests
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and/or anterior cerebral artery, DDFPe reduced infarct size in
our mouse model of permanent LAD occlusion-induced MI.
Despite experiencing a similar ischemic area, as assessed by
the area at risk, mice treated with DDFPe immediately fol-
lowing initiation of the ischemic event by LAD ligation ex-
perienced a significantly smaller infarct. Of particular note, is
the difference in DDFPe dosing regimens between our study
and the work performed by Culp et al. in the rabbit stroke
model. Culp et al. used repeated DDFPe injections (0.6 ml/kg)
at 90 min intervals throughout the course of the experiments.
In a follow up this work, it was demonstrated that DDFPe
doses as small as 0.1 ml/kg given every 90 min were similarly
effective in reducing infarct size in the rabbit stroke model
[10]. In this study we used a single injection of DDFPe
(0.6 ml/kg) administered at the onset of ischemia. These
differences in dosing schedules provide valuable insight into
a potential mechanism of DDFPe elicited protection against
ischemia.
In order to understand the significance of the difference in
dosing regimens as it relates to the mechanism of protection
against ischemia, it is necessary to understand the pharmaco-
kinetic profile of DDFPe. In normal healthy volunteers, the
pharmacokinetics of DDFPe administered intravenously fits a
two-compartment model. What is taken up by the various
tissues presumably depends on the degree of local tissue
oxygenation, however DDFPe is undetectable after approxi-
mately 8 h (personal communication with NuvOx). DDFPe is
highly inert and does not undergo any detectable metabolism
or biotransformation within the body. DDFPe is eliminated
almost entirely through expiration and has a very short half-
life of 2.2±1.2 min in the blood, with nearly all DDFPe being
recovered in expired air by 2 h after administration [15].
Although these studies were performed in humans, the inert
nature and physiochemical properties of DDFPe suggest that a
similar pharmacokinetic profile should be observable across
species. Pharmacokinetic analysis of a single dose of DDFPe
in rabbits revealed a comparable profile with a blood half-life
of 1.45±0.17 min [10].
Given the short half-life of DDFPe, the repeated 90 min
dosing may be practical in order to ensure sustained oxygen
delivery to the ischemic area by DDFPe. However, we were
able to observe a cardiac protective effect using only a single
IV dose of DDFPe in our model of 24 h LAD occlusion. As
DDFPe should be eliminated from the system well before
24 h, it raises the question of how a single dose of DDFPe is
able to reduce infarct size so dramatically. Similarly, in a
follow-up to the work done by Culp et al., it was observed
that even with repeated dosing, DDFPe maintained neuropro-
tection beyond its retention time in the body [10]. We propose
that oxygen delivery by DDFPe to the ischemic tissue is
slowly diminished over time as DDFPe is eliminated,
resulting in an increasingly hypoxic environment. We believe
this slow advancement to hypoxia is able to reduce infarct size
by mimicking certain events that occur during ischemic pre-
conditioning (Fig. 3).
Ischemic preconditioning (IPC) is a well characterized
phenomenon, whereby short cycles of ischemia and reperfu-
sion are able to protect the heart from subsequent long term
ischemic insults. IPC initiates a plethora of signaling events
mediated by triggers such as adenosine, bradykinin, and opi-
oids [16]. These IPC triggers converge on several downstream
mediators to elicit the protective effects. A key mediator of
IPC is activation of the mitochondrial ATP-sensitive potassi-
um channel (mitoKATP) [17]. While direct activation of
mitoKATP by diazoxide is sufficient to elicit pharmacological
IPC, the mitoKATP inhibitors glibenclamide and 5-
hydroxydecanoate (5-HD) block both classical IPC and as
well as many methods of pharmacological IPC, highlighting
its importance [18–21].
In order to elucidate a potential role of mitoKATP and IPC in
DDFPe-induced cardiac protection, the mitoKATP inhibitor 5-
HD was utilized. 5-HD was chosen over glibenclamide based
on greater specificity for the mitoKATP over the sarcoplasmic
KATP channel [22–24]. Pretreatment with 5-HD prior to LAD
occlusion did not appreciably alter infarct size (36.9±4.2 %
for vehicle vs 29.2±4.4 % for 5-HD) or cTnI release (35.0±
4.6 ng/ml for vehicle vs 27.4±5.1 ng/ml for 5-HD). However,
5-HD pretreatment blocked the decrease in infarct size asso-
ciated with DDFPe alone, supporting an IPC-like event me-
diated by mitoKATP as the mechanism of DDFPe cardiac
protection, as illustrated in Figure 4.
Our results demonstrated that DDFPe elicits a cardiac
protective effect that persists well beyond the assumed elim-
ination time of DDFPe. The initiating events that lead to
sustained cardiac protection are likely the result of the oxygen
delivery provided by DDFPe early on, as DDFPe is highly
inert and has not been reported to interact directly with any
signaling pathways. However, our data indicate that DDFPe
elicits protection through the same mediator as many IPC
triggers, providing potential leads to investigate the exact
Fig. 4 Proposed Model of Cardiac Protection by DDFPe. Blue indicates
periods of ischemia (I), while red represents periods of reperfusion (R) or
oxygen delivery by DDFPe. The red to blue color fade-in depicted during
DDFPe period represents the proposed gradual decrease in oxygen de-
livery that occurs as DDFPe is eliminated from the system
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signaling pathways responsible. Perhaps the most likely trig-
ger is an increase in reactive oxygen species (ROS), which
have been identified as an important mediator required for
both mitoKATP activation and IPC [25–27]. The increased
generation of ROS has been a potential concern with en-
hanced oxygen delivery systems such as DDFPe, but the
influence of DDFPe on ROS production in vivo has yet to
be investigated. Although, the deleterious effects of ROS in
numerous pathologies have been well documented, ROS can
also play a protective role in low dose or short-term exposures,
as with IPC. If DDFPe does in fact increase ROS production,
it is possible that a single administration of DDFPe may be
more advantageous to elicit a preconditioning effect without
the subsequent damage caused by excessive ROS from re-
peated dosing.
One of the pitfalls of IPC is the necessity for the precondi-
tioning to occur prior to ischemia, which is impractical in the
clinical setting as patients presenting to the emergency room
have already experienced an ischemic event. However, it has
been observed that many of the initiating triggers of IPC also
elicit protection when initiated prior to reperfusion, a process
termed post-conditioning [28]. In addition to being initiated
by many of the same triggers as IPC, post-conditioning is
mediated by similar mechanisms, including activation of the
mitoKATP [28, 29]. The dependence of DDFPe on mitoKATP
for cardiac protection in this model suggests that DDFPe may
be effective in initiating post-conditioning like protection as
well. Although this study did not address the utility of DDFPe
on post-conditioning, studies investigating the protective po-
tential of DDFPe administered after a period of ischemia, but
prior to complete reperfusion are warranted. It is particularly
important to assess the protective potential of DDFPe in a
model of reperfusion as this is more clinically relevant to
revascularization that occurs following an acute myocardial
infarction.
This observation that DDFPe is able to stimulate cardiac
protection through an IPC-like mechanism represents an ex-
citing discovery in the field of PFC oxygen delivery. The sole
therapeutic potential of PFC has always been assumed to stem
from the gas delivery properties, specifically the ability to
supplement oxygen delivery; however, the data presented here
suggests that the protective effects extend beyond the
timeframe of elimination from the system. Such a lasting
protective effect offers many potential benefits that may be
applied clinically. As the time to reperfusion initiation is
critical to limiting myocardial damage following an ischemic
event, the use of DDFPe can extend the window of optimal
reperfusion. Myocardial cell injury can occur within 20–
30 min of ischemia; however, myocardial necrosis can take
several hours to develop and even a 1–2 h extension in the
timeframe of optimal reperfusion would have significant im-
pact on survival and recovery from MI. In addition, even in
the absence of reperfusion DDFPe produced dramatic cardiac
protection observable out to 24 h after LAD occlusion. As
reperfusion is the most important therapy to reduce myocar-
dial injury following an ischemic, DDFPe may have a more
pronounced protective effect when combined with
reperfusion.
DDFPe has already been demonstrated to be safe in
humans. Moreover, DDFPe is stable when stored at room
temperature which makes it an ideal candidate for future
development into clinical practice as it may be administered
in the initial treatment of ischemic events by first responders.
Furthermore, if DDFPe is in fact initiating mechanisms of IPC
it may offer additional therapeutic potential. The protective
effects of IPC are not limited to the myocardium and IPC has
been shown to be protective in other ischemic tissue as well,
including stroke and organ transplantation, suggesting a po-
tential use of DDFPe IPC-like protection in these applications
[30–33].
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